Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 1 of 7, showing 5 Applications out of 33 total, starting on record 1, ending on 5

# Protocol No Study Title Investigator(s) & Site(s) Application Status

1.

ECCT/20/10/01   HIV-CORE 006
    A Phase 1 Trial of ChAdOx1- and MVA-vectored Conserved Mosaic HIV-1 Vaccines in Healthy, Adult HIV-1-negative Volunteers in Eastern and Southern Africa.    
Principal Investigator(s)
1. Eduard J Sanders
Site(s) in Kenya
1. KEMRI Mtwapa Research Clinic (Kilifi county)
2. KAVI-ICR Nairobi (Nairobi City county)
 
Trial Status (not set!)
Protocol Date 06-05-2020
View

2.

ECCT/20/07/02   RV 460 HIV Vaccine Trial
    A Randomized, Double-Blind Phase 1 Trial to Evaluate the Safety and Immunogenicity of   Priming with Env-C Plasmid DNA Vaccine Alone, with Different Adjuvants, or with an   Adjuvanted HIV Env gp145 C.6980 Protein Vaccine and Boosting with the Adjuvanted   HIV Env gp145 C.6980 Protein Vaccine with or without the Env-C Plasmid DNA Vaccine   in Healthy HIV Uninfected Adults in Kenya   
Principal Investigator(s)
1. Josphat Kosgei
Site(s) in Kenya
KEMRI/US MRDA-A/K, KERICHO
 
Trial Status Not yet recruiting
Protocol Date 29-02-2020
View

3.

ECCT/20/06/09   HIV-CORE 006
    A Phase 1 Trial of ChAdOx1- and MVA-vectored Conserved Mosaic HIV-1 Vaccines in Healthy, Adult HIV-1-negative Volunteers in Eastern and Southern Africa   
Principal Investigator(s)
1. Professor Walter Jaoko, Jaoko,
Site(s) in Kenya
1. KAVI-Institute of Clinical Research (Nairobi City county)
2. KEMRI/ Wellcome Trust Research Programme (Kilifi county)
 
Trial Status (not set!)
Protocol Date 02-01-2020
View

4.

ECCT/20/05/01   ChAdOx1 nCoV-19 trial
    A phase Ib/II single-blinded, randomised, controlled study to determine safety, immunogenicity and efficacy of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults in Kenya   
Principal Investigator(s)
1. George Warimwe
Site(s) in Kenya
KEMRI-CGMRC
 
Trial Status Not yet recruiting
Protocol Date 28-04-2020
View

5.

ECCT/20/06/01   IAVI C100
    Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults   
Principal Investigator(s)
1. Dr Gaudensia Nzembi Mutua Nzembi Mutua
Site(s) in Kenya
1. KAVI-Insitute of Clinical Research, KNH site (Nairobi City county)
 
Trial Status (not set!)
Protocol Date 13-12-2019
View